Application of fluorimetric analysis of plant esterases to study of programmed cell death and effects of cadmium(II) ions

被引:8
|
作者
Vitecek, J.
Petrlova, J.
Petrek, J.
Adam, V.
Havel, L.
Kramer, K. J.
Kizek, R.
机构
[1] Mendel Univ Agr & Forestry, Dept Plant Biol, CZ-61300 Brno, Czech Republic
[2] Mendel Univ Agr & Forestry, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic
[3] Masaryk Univ, Fac Sci, Dept Analyt Chem, CZ-61137 Brno, Czech Republic
[4] Grain Mkt & Prod Res Ctr, USDA, Agr Res Serv, Manhattan, KS 66502 USA
关键词
attomole detection; confocal microscopy; early somatic embryos of Norway spruce; fluorescein diacetate; fluorescence microscopy; protoplast; tobacco BY-2;
D O I
10.1007/s10535-007-0119-4
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Esterases (EC 3.1.1.x) represent a diverse group of hydrolases catalyzing the cleavage and formation of carboxyl ester bonds. Their connection with development has made them a suitable marker of development in plants. In the present work, we focused on the fluorimetric determination of the plant esterases in plant cell cultures (tobacco BY-2 cells and early somatic embryos of Norway spruce, clone 2/32) with respect to application the method for the study of programmed cell death and the influence of cadmium(II) ions on the plant cells. The programmed cell death has been triggered by sodium nitroprusside and glucose oxidase. The determination of the esterase activity by the proposed technique in a cell extract determined very small difference in enzyme activity, which was a reliable marker of metabolic changes. In addition, the esterase activity of spruce somatic embryos decreased with the increase in medium Cd concentration.
引用
收藏
页码:551 / 555
页数:5
相关论文
共 50 条
  • [31] Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
    Rossille, D.
    Azzaoui, I.
    Feldman, A. L.
    Maurer, M. J.
    Laboure, G.
    Parrens, M.
    Pangault, C.
    Habermann, T. M.
    Ansell, S. M.
    Link, B. K.
    Tarte, K.
    Witzig, T. E.
    Lamy, T.
    Slager, S. L.
    Roussel, M.
    Milpied, N.
    Cerhan, J. R.
    Fest, T.
    LEUKEMIA, 2017, 31 (04) : 988 - 991
  • [32] Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study
    Yang, Qinzhu
    Huang, Haofan
    Zhang, Guizhi
    Weng, Nuoqing
    Ou, Zhenkai
    Sun, Meili
    Luo, Huixing
    Zhou, Xuhui
    Gao, Yi
    Wu, Xiaobin
    THORACIC CANCER, 2023, 14 (33) : 3266 - 3274
  • [33] A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
    Pujol, Jean-Louis
    Greillier, Laurent
    Audigier-Valette, Clarisse
    Moro-Sibilot, Denis
    Uwer, Lionel
    Hureaux, Jose
    Guisier, Florian
    Carmier, Delphine
    Madelaine, Jeannick
    Otto, Josiane
    Gounant, Valerie
    Merle, Patrick
    Mourlanette, Pierre
    Molinier, Olivier
    Renault, Aldo
    Rabeau, Audrey
    Antoine, Martine
    Denis, Marc G.
    Bommart, Sebastien
    Langlais, Alexandra
    Morin, Franck
    Souquet, Pierre-Jean
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 903 - 913
  • [34] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA (NPC) WHO HAD PROGRESSED AFTER TWO OR MORE LINES OF CHEMOTHERAPY
    Chen, Xiaozhong
    Wang, Wei
    Zou, Qingfeng
    Li, Jingao
    Hu, Chaosu
    Hu, Chaosu
    Lin, Qin
    Zhu, Xiaodong
    Jiang, Yi
    Sun, Yan
    Shen, Liangfang
    Wang, Lin
    Zou, Guorong
    Lin, Xiaoyan
    Wang, Ying
    Lin, Shaojun
    Li, Minying
    Ao, Rui
    Xu, Ruilian
    Lin, Haifeng
    Wang, Rensheng
    Yang, Jiacheng
    Song, Weifeng
    Wang, Max
    Li, Baiyong
    Xia, Yu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A481 - A481
  • [35] 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
    Gerhard-Hartmann, Elena
    Goergen, Helen
    Broeckelmann, Paul J.
    Mottok, Anja
    Steinmueller, Tabea
    Grund, Johanna
    Zamo, Alberto
    Ben-Neriah, Susana
    Sasse, Stephanie
    Borchmann, Sven
    Fuchs, Michael
    Borchmann, Peter
    Reinke, Sarah
    Engert, Andreas
    Veldman, Johanna
    Diepstra, Arjan
    Klapper, Wolfram
    Rosenwald, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 116 - 126
  • [36] A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
    Vidula, Neelima
    Goga, Andrei
    Hwang, Jimmy
    Liu, Minetta C.
    Park, Ben Ho
    Nanda, Rita
    Pohlmann, Paula Raffin
    Storniolo, Anna Maria
    Brufsky, Adam
    Abramson, Vandana Gupta
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
    Chen, X.
    Hu, C.
    Wang, W.
    Zou, Q.
    Li, J.
    Lin, Q.
    Zhu, X.
    Jiang, Y.
    Sun, Y.
    Shen, L.
    Wang, L.
    Zou, G.
    Lin, X.
    Wang, Y.
    Lin, S.
    Li, M.
    Ao, R.
    Xu, R.
    Lin, H.
    Wang, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [38] Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
    Pasqualini, Claudia
    Rubino, Jonathan
    Brard, Caroline
    Cassard, Lydie
    Andre, Nicolas
    Rondof, Windy
    Scoazec, Jean-Yves
    Marchais, Antonin
    Nebchi, Souad
    Boselli, Lisa
    Grivel, Jonathan
    Aerts, Isabelle
    Thebaud, Estelle
    Paoletti, Xavier
    Minard-Colin, Veronique
    Vassal, Gilles
    Geoerger, Birgit
    EUROPEAN JOURNAL OF CANCER, 2021, 150 : 53 - 62
  • [39] Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma.
    Wang, Fenghua
    Wei, Xiao-Li
    Feng, Jifeng
    Li, Qi
    Xu, Nong
    Hu, Xichun
    Liao, Wangjun
    Jiang, Yi
    Lin, Xiaoyan
    Zhang, Qingyuan
    Yuan, Xianglin
    Huang, Haixin
    Chen, Ye
    Dai, Guanghai
    Shi, Jianhua
    Shen, Lin
    Yang, Shujun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients
    Saito, Tomohito
    Tsuta, Koji
    Ishida, Mitsuaki
    Ryota, Hironori
    Takeyasu, Yuki
    Fukumoto, Kento J.
    Matsui, Hiroshi
    Taniguchi, Yohei
    Yanagimoto, Hiroaki
    Kurata, Takayasu
    Murakawa, Tomohiro
    LUNG CANCER, 2018, 125 : 230 - 237